Cargando…

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog

The over two dozen CYP2B structures of human, rabbit, and woodrat enzymes solved in the last decade have significantly enhanced our understanding of the structure-function relationships of drug metabolizing enzymes. More recently, an important role has emerged for halogen-π interactions in the CYP2B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Manish B., Zhang, Qinghai, Halpert, James R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979536/ https://www.ncbi.nlm.nih.gov/pubmed/29596329 http://dx.doi.org/10.3390/ijms19041025

Ejemplares similares

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz
por: Mardi, Parham, et al.
Publicado: (2022)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
por: Meng, Xianmin, et al.
Publicado: (2015)

Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV
por: Hui, KH, et al.
Publicado: (2016)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
por: Soeria-Atmadja, Sandra, et al.
Publicado: (2017)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe
por: Dhoro, Milcah, et al.
Publicado: (2015)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
por: Maseng, Monkgomotsi J, et al.
Publicado: (2021)

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
por: Kitabi, Eliford Ngaimisi, et al.
Publicado: (2018)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]
Publicado: (2021)

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity
por: Petros, Zelalem, et al.
Publicado: (2022)

The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana
por: Maseng, Monkgomotsi J., et al.
Publicado: (2022)

CYP46A1-dependent and independent effects of efavirenz treatment
por: Mast, Natalia, et al.
Publicado: (2020)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study
por: Tadesse, Wondmagegn Tamiru, et al.
Publicado: (2022)

Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation
por: Pinillos, Francoise, et al.
Publicado: (2016)

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis
por: Nightingale, Sam, et al.
Publicado: (2016)

Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele
por: Bordin Andriguetti, Natália, et al.
Publicado: (2021)

The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics
por: Bunu, Samuel J, et al.
Publicado: (2022)

Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients
por: Gounden, Verena, et al.
Publicado: (2010)

Crystal structure of Rb(6)[B(12)O(18)(OH)(6)]·2H(2)O
por: Qiu, Qi-Ming, et al.
Publicado: (2022)

HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz
por: Drury, Andrew, et al.
Publicado: (2018)

2-{(1E)-[(E)-2-(2,6-Dichlorobenzylidene)hydrazin-1-ylidene]methyl}phenol: crystal structure, Hirshfeld surface analysis and computational study
por: Manawar, Rohit B., et al.
Publicado: (2019)

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
por: Uttayamakul, Sumonmal, et al.
Publicado: (2010)

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study
por: Damronglerd, Pansachee, et al.
Publicado: (2015)

Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings
por: Thomford, Nicholas E., et al.
Publicado: (2016)

Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study
por: Buzibye, Allan, et al.
Publicado: (2023)

Does efavirenz replacement improve neurological function in treated HIV infection?
por: Payne, B, et al.
Publicado: (2017)

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6
por: Ke, A, et al.
Publicado: (2016)

Crystal structure, Hirshfeld surface analysis and computational study of bis(2-{[(2,6-dichlorobenzylidene)hydrazinylidene]methyl}phenolato)cobalt(II) and of the copper(II) analogue
por: Manawar, Rohit B., et al.
Publicado: (2020)

Crystal structure of Cs(2)[Th(NO(3))(6)]
por: Woidy, Patrick, et al.
Publicado: (2014)

Crystal structure of yeast monothiol glutaredoxin Grx6 in complex with a glutathione-coordinated [2Fe–2S] cluster
por: Abdalla, Mohnad, et al.
Publicado: (2016)

Crystal structures of bis- and hexakis[(6,6′-dihydroxybipyridine)copper(II)] nitrate coordination complexes
por: Gerlach, Deidra L., et al.
Publicado: (2015)

The crystal structure of DR6 in complex with the amyloid precursor protein provides insight into death receptor activation
por: Xu, Kai, et al.
Publicado: (2015)

Crystal structures of two dis-symmetric di-Schiff base compounds: 2-({(E)-2-[(E)-2,6-dichlorobenzylidene]hydrazin-1-ylidene}methyl)-6-methoxyphenol and 4-bromo-2-({(E)-2-[(E)-2,6-dichlorobenzylidene]hydrazin-1-ylidene}methyl)phenol
por: Manawar, Rohit B., et al.
Publicado: (2020)

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
por: Ngaimisi, Eliford, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3ous5c28ckrf76f8lf18qiet00